Related Experiment Video
Updated: Mar 13, 2026
Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL
Published on: July 19, 2024
Using zebrafish models of leukemia to streamline drug screening and discovery
Adam P Deveau1, Victoria L Bentley2, Jason N Berman3
1Department of Pediatrics, IWK Health Centre, Halifax, Nova Scotia, Canada.
Abstract:
Current treatment strategies for acute leukemias largely rely on nonspecific cytotoxic drugs that result in high therapy-related morbidity and mortality. Cost-effective, pertinent animal models are needed to link in vitro studies with the development of new therapeutic agents in clinical trials on a high-throughput scale. However, targeted therapies have had limited success moving from bench to clinic, often due to unexpected off-target effects. The zebrafish has emerged as a reliable in vivo tool for modeling human leukemia. Zebrafish genetic and xenograft models of acute leukemia provide an unprecedented opportunity to conduct rapid, phenotype-based screens. This allows for the identification of relevant therapies while simultaneously evaluating drug toxicity, thus circumventing the limitations of target-centric approaches.
Insights
Zebrafish models offer a cost-effective way to test leukemia therapies. This approach rapidly identifies effective treatments and evaluates drug toxicity, improving drug development for acute leukemias.
Area of Science:
- * Hematology
- * Oncology
- * Zebrafish models
Background:
- * Current acute leukemia treatments use nonspecific cytotoxic drugs, leading to significant side effects.
- * Developing new therapies is hindered by challenges in translating targeted treatments from lab to clinic.
- * There is a need for efficient, cost-effective animal models to bridge the gap between in vitro studies and clinical trials.
Purpose of the Study:
- * To highlight the utility of zebrafish models for acute leukemia research.
- * To demonstrate the potential of zebrafish for high-throughput screening of therapeutic agents.
- * To evaluate the effectiveness of phenotype-based screening in identifying relevant therapies and assessing toxicity.
Main Methods:
- * Utilizing zebrafish genetic and xenograft models of acute leukemia.
- * Conducting rapid, phenotype-based screens for therapeutic agents.
- * Evaluating drug toxicity alongside therapeutic efficacy in vivo.
Main Results:
- * Zebrafish models provide a reliable in vivo system for human leukemia.
- * Phenotype-based screening enables rapid identification of potential therapies.
- * This approach allows for simultaneous evaluation of drug toxicity, addressing off-target effects.
Conclusions:
- * Zebrafish models are valuable tools for accelerating acute leukemia drug discovery.
- * Phenotype-based screening in zebrafish circumvents limitations of traditional target-centric approaches.
- * This strategy can improve the translation of novel therapies from research to clinical application.
